Tivozanib hydrochloride monohydrate is a tyrosine kinase inhibitor. In vitro cell kinase assays have shown that tevozanib hydrochloride monohydrate can inhibit the phosphorylation of vascular endothelial growth factor receptor (VEGFR-1), VEGFR-2, and VEGFR-3 at clinically relevant concentrations, as well as inhibit other kinases, including c-kit and PDGFR β。 And tumor growth of various types of tumor cells (including human renal cell carcinoma).